• WCLC 2024 | Nivolumab’s Perk in Perioperative NSCLC: CheckMate 77T & 816 Unveil 40% Recurrence Slash

    A patient-level analysis of the phase III CheckMate 77T trial (NCT04025879) and the phase III CheckMate 816 trial (NCT02998528) revealed that perioperative treatment with nivolumab for resectable non-small cell lung cancer (NSCLC) patients reduces the risk of disease recurrence or death by approximately 40%, compared to neoadjuvant nivolumab plus chemotherapy alone. This article presents Dr.…

  • WCLC 2024丨Furmonertinib Blazes New Trail in EGFR PACC NSCLC: A Quantum Leap in Precision Oncology

    EGFR P-loop-aC helix compression (PACC) mutation is a recently identified subtype of EGFR mutations in non-small cell lung cancer (NSCLC), and its potential for precision therapy had not been clinically validated until now. At the 2024 World Conference on Lung Cancer (WCLC 2024), during the Presidential Symposium Presentation, the global phase Ib FURTHER trial’s proof-of-concept…

  • WCLC 2024 | DUBLIN-3 Study Shatters Second-Line NSCLC Treatment Paradigm with Plinabulin Combination

    The 2024 World Conference on Lung Cancer (WCLC), taking place from September 7-10 in San Diego, USA, will showcase key findings from Chinese researchers, including a phase III randomized controlled trial comparing plinabulin plus docetaxel versus docetaxel alone for the treatment of advanced non-small cell lung cancer (NSCLC) after progression on platinum-based chemotherapy. The results…

  • WCLC 2024 Breakthrough: FLOWERS Trial Sheds Light on Advanced NSCLC Treatment

    During the second Presidential Symposium at the 2024 World Conference on Lung Cancer (WCLC), Professor Jing-Ji Yang from Guangdong Provincial People’s Hospital presented the report “Osimertinib with or without Savolitinib as First-Line Treatment for De Novo MET Aberrant, EGFRm Advanced Non-Small Cell Lung Cancer (NSCLC) (CTONG 2008): Results from the Phase II FLOWERS Clinical Trial.”

  • CSCO 2024丨Advancing NSCLC Treatment: Dr. Changli Wang on the Promise of Perioperative Immunotherapy

    The 27th Annual National Clinical Oncology Conference and 2024 CSCO Academic Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, took place in Xiamen from September 25 to 29, 2024. Multiple forums on lung cancer were held during the conference, summarizing the latest advances in…

  • ESMO 2024 Highlights: Dr. Ben J. Solomon on Alectinib’s Biomarker Analysis

    The 2024 European Society for Medical Oncology (ESMO) Congress took place from September 13 to 17 in Barcelona, Spain, where significant progress in lung cancer research was unveiled. Dr. Ben J. Solomon, from the Peter MacCallum Cancer Centre in Melbourne, Australia, shared the results of the biomarker analysis from the ALINA study. In an exclusive…

  • ESMO 2024 Update: Dr. Xiao Chen on Ilourac’s Sustained PFS Benefits

    Ilourac (WX-0593) is a next-generation, potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), showing both systemic and central nervous system (CNS) efficacy in patients with ALK-positive non-small cell lung cancer (NSCLC). At the 2024 ESMO Congress, updated data from the INSPIRE study were presented in a poster session, showing continued progression-free survival (PFS) improvement…

  • ESMO 2024 Insights: Dr. Jie Chen on CABINET and CVM-005 Trials in NETs

    The 2024 European Society for Medical Oncology (ESMO) Annual Meeting has successfully concluded. Several studies presented during the neuroendocrine tumor (NET) oral sessions have offered new treatment strategies and molecular profiling for advanced unresectable NETs. Notably, the Phase III CABINET study on cabozantinib achieved its primary endpoint of progression-free survival (PFS), and the multi-center single-arm…